*Patients with missing results not included.

The majority of patients in the study had one prior therapy. Chemotherapy with or without anti-CD20 was the most common prior therapy 2

VEN+R= VENCLEXTA + rituximab; BR=bendamustine + rituximab; ECOG=Eastern Cooperative Oncology Group; CLL=chronic lymphocytic leukemia; TP53=tumor protein 53; IgVH=immunoglobulin variable-region heavy-chain gene; FCR=fludarabine, cyclophosphamide, rituximab